How government shutdown affects healthtech and medtech founders

Health-tech isn’t sexy anymore, and that’s exactly why it’s getting real. The hype kids have left the room. The adults with data, compliance, and patience just walked in. Deals are happening quietly. M&A is the new funding round. Startups are learning the hard way that “AI for healthcare” means nothing if you can’t pass a clinical trial or integrate with a hospital’s 1990s software. The valuations? Coming back to earth. The noise? Finally fading. The winners? The ones who can sell both to a doctor and a regulator. This is where the real game starts. Health-tech isn’t a revolution anymore, it’s a takeover. Agree or not, this next wave won’t be about hype. It’ll be about who survives the compliance call.

I joined Nicole Barbano-Sipe of Hunter Ambrose Int. on her podcast to talk about what it really takes to bring AI-powered medical devices to market, not just the science, but the systems. We covered: --What founders misunderstand about the FDA (and why I actually find the agency reasonable) --How product and regulatory strategy are the same problem framed from two sides --Why the real blockers to market aren’t always the regulators, its the workflow misalignments, procurement gates, and silent stakeholders that follow --And the difference between a pain point and actual demand --A Last of Us moment If you’re building in digital health or regulated AI, this conversation goes beyond compliance theory. It’s about designing for the whole system: clinicians, committees, and capital. Link in the comments. #DigitalHealth #MedTech #AIProductManagement #ComplianceInnovation #GoToMarket #FDA #HealthcareStartups

Digital twin technology is transforming the clinical trial landscape by creating virtual models of patients to simulate responses to treatments. This innovation reduces the need for large control groups, accelerates timelines, and enhances the precision of trial outcomes. As regulatory frameworks evolve, digital twins are becoming a cornerstone of adaptive and patient-centric research. The future of clinical trials is faster, smarter, and more efficient. #ClinicalTrials #ClinicalResearch https://lnkd.in/eYH-kNR6 

Not all breakthroughs make headlines—some quietly reshape entire industries. Harrison.ai has just earned three Breakthrough Device Designations from the U.S. FDA for its innovations in medical imaging. What's remarkable isn’t just the recognition—but the signal it sends about where intelligent systems are taking us. What we’re seeing is more than just smarter diagnostics. We're watching a shift in how businesses, both large and small, engage with complex challenges. From healthcare to logistics, retail to manufacturing—integrating intelligent systems into operations is no longer optional. It’s becoming core to maintaining relevance. Consider the healthcare sector: Tools that can rapidly interpret medical scans don’t just improve diagnostic accuracy; they reduce waiting times, ease pressure on specialists, and help clinics scale care without proportionally increasing headcount. That's operational efficiency at work. For businesses, this means opportunities to do more with less—streamline customer service, optimize inventory, forecast demand, or spot errors before they escalate. The potential spans beyond medtech. I’m always interested in meaningful conversations and would love to connect with others curious about where intelligent tools are going—and how we can use them intentionally. More about what we're building here: Ava-desk.com

The global clinical trials landscape is undergoing a remarkable transformation evolving from traditional, siloed studies to interconnected, data-driven ecosystems that redefine how science reaches patients. With expanding datasets, multi-country logistics, adaptive protocols, and real-world data integration, the process of bringing new therapies to life, is becoming more dynamic than ever before. But with innovation comes complexity, heightened operational demands, evolving regulatory frameworks, and the constant need for precision and transparency. As the backbone of medical advancement, clinical trials now stand at the intersection of technology, science, and human impact — a perspective underscored by John Dawber. Read the latest edition now :https://lnkd.in/g58i3m7T #ETEdgeInsights #ETEdgeInsightsMagazine #ClinicalTrials #MedTech #DataDrivenEcosystem #RealWorldData #AdaptiveTrials

Life Sciences + IT = The Future 🎯 Show life sciences digital transformation perspective. 🖼️ Slides: 1. Cover — “Life Sciences + IT = The Future of Health” 2. R&D automation 3. Clinical trial analytics 4. Digital twins in drug discovery 5. Regulatory compliance tech 6. Impact on patients & scientists 7. CTA: “Are you ready for TechBio?” 💡 Caption: The next frontier isn’t just healthcare—it’s TechBio.

Reducing Misdiagnosis, One Algorithm at a Time. 🔁 Clinicians face data overload and fragmented systems — making accurate diagnosis harder than it should be. At Silstone, we help HealthTech teams embed AI-driven analytics and clinical intelligence directly into their products — turning scattered data into real-time insights. 🤖 -Better accuracy -Faster workflows -Improved outcomes #HealthTech #AIinHealthcare #DigitalHealth #MedTech #ClinicalAI #PatientSafety

As the boundary between mind and machine begins to blur, a new era of human potential begins to take shape. Speaking at #FII9, Max Hodak, Founder & CEO of Science, explored how #neurotechnology may redefine #healthcare, shifting from treating illness to extending life. He highlighted the need for new models to make medical #innovation as scalable and transformative as #tech itself. Watch the livestream: https://bit.ly/FII9_DAY3A

Biotech Is Repricing Risk while Digital Health Reprices Evidence This week the market sent three clear signals that are hard to ignore. First, public biotech stayed choppy while secondary offerings again outnumbered IPOs. That tells me capital is open for execution stories but not for promises. Companies with clean data packages and realistic cash runways still get filled. Narratives without near term catalysts struggle. Second, payer pressure is now the silent gatekeeper of adoption. Across my calls with operators and clinicians, the question is no longer whether a therapy or tool works in a study. The question is whether it changes total cost of care within one budget cycle. If a product cannot show measurable savings or time to value, pilots stall. Third, AI in health is moving from hype to habit. Buyers want auditable datasets, clear governance, and repeatable workflow gains. I am seeing fewer giant announcements and more quiet integrations that cut turnaround time in imaging, triage, and revenue cycle. The winners are pairing model quality with boring but essential plumbing such as data provenance and security. My take is simple. The cycle is not broken. It is maturing. Teams that couple clinical rigor with operational discipline will outrun the volatility. Platform builders who treat reimbursement and hospital workflow as design inputs will keep raising. Everyone else is about to learn that product market fit in healthcare means payer provider proof, not pitch deck poetry. What are you seeing this week. Are investors finally rewarding evidence over excitement #Biotech #DigitalHealth #LifeSciences #ClinicalTrials #HealthEconomics #VentureCapital #MedTech #AI #HealthcareInnovation #Strategy #InsightPartners #JohnsHopkins #LauderInstitute